Comparative, Prospective, Multi-Center, Open, Randomized Study to Investigate Bleeding Patterns, Metabolic Effects, Contraceptive Efficacy, Acceptance, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 2 mg Dienogest, in Two Different Regimens of Intake (Four Extended Cycles of 84 Days Each Versus the Conventional Regimen of 21 Days) in Healthy Volunteers.
Phase of Trial: Phase III
Latest Information Update: 01 Jan 2010
At a glance
- Drugs Ethinylestradiol/dienogest (Primary)
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Bayer
- 20 May 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 21 Jul 2006 New trial record.